Palvella Therapeutics Reports $15.8M Net Loss and $206.4M Cash Reserves in Latest 10-Q

Palvella Therapeutics, Inc. reported significant financial developments in its latest 10-Q filing for the quarter ending March 31, 2026. The company recorded a net loss of $15.8 million, a 93% increase from the $8.2 million loss reported in the same period last year. Total operating expenses rose to $14.9 million, up 89% from $7.9 million in the prior year, primarily driven by increased research and development costs, which surged by 129% to $9.3 million. General and administrative expenses also increased by 45% to $5.5 million, reflecting the costs associated with operating as a public company following the recent merger.

The company’s cash and cash equivalents saw a substantial increase, reaching $206.4 million as of March 31, 2026, compared to $58.0 million at the end of the previous fiscal year. This increase was bolstered by a successful equity financing round in February 2026, which generated net proceeds of approximately $215.8 million. The financing involved the issuance of 1.6 million shares of common stock at a public offering price of $125 per share, with an additional option for underwriters to purchase more shares, which was fully exercised.

Palvella has made strategic advancements in its product pipeline, particularly with its lead candidate, QTORIN rapamycin, which is in clinical development for various rare skin diseases. The company announced positive topline results from its Phase 3 SELVA trial for microcystic lymphatic malformations and a Phase 2 trial for cutaneous venous malformations. Additionally, Palvella is expanding its research into clinically significant angiokeratomas and has initiated a Phase 2 trial for this indication. The company has also received Breakthrough Therapy Designation from the FDA for QTORIN rapamycin, indicating its potential significance in treating these conditions.

Operationally, Palvella's employee headcount has increased as it expands its capabilities to support clinical trials and product development. The company is focused on advancing its product candidates through regulatory approvals and commercialization, with expectations of incurring significant expenses related to these efforts. Management has indicated that while they have sufficient funds to support operations for at least the next year, they may need to seek additional financing to continue their development programs and meet future operational needs. The outlook remains contingent on the successful progression of clinical trials and the regulatory landscape, which could impact the timing and costs associated with bringing their products to market.